- Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B Endpoints News
- Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal WSJ
- Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Reuters
- Merck KGaA to purchase SpringWorks Therapeutics in deal worth more than $3 billion statnews.com
- Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business Business Wire